(NP -LCB-/-LRB- (NP Effect/NN) (PP of/IN (NP (NP antihypertensive/JJ therapy/NN) (PP with/IN (NP captopril/NN)))) (PP on/IN (NP (NP (NP-COOD (NP (NP gluco-/JJ) (NP *?*/-NONE-)) and/CC (NP mineralocorticoid/NN)) receptors/NNS) (PP of/IN (NP (NP peripheral/JJ blood/NN lymphocytes/NNS) (PP in/IN (NP (NP hypertensive/JJ patients/NNS) (PP of/IN (NP various/JJ age/NN)))))))) -RCB-/-RRB-)
(S (NP-SBJ-52 (NP Binding/NN) (PP of/IN (NP-COOD (NP 3H-dexamethasone/NN) and/CC (NP 3H-aldosterone/NN))) (PP by/IN (NP peripheral/JJ lymphocyte/NN receptors/NNS))) (VP was/VBD (VP investigated/VBN (NP *-52/-NONE-) (PP in/IN (NP-COOD (NP healthy/JJ persons/NNS) and/CC (NP hypertensive/JJ patients/NNS))) (PP-TMP (PP-COOD (PP before/IN (NP *RNR*-53/-NONE-)) and/CC (PP after/IN (NP *RNR*-53/-NONE-))) (NP-53 (ADJP 2-week/JJ) captopril/NN treatment/NN)))) ./.)
(S (NP-SBJ-54 (NP The/DT number/NN) (PP of/IN (NP (NP-COOD (NP glucocorticoid/NN) and/CC (NP mineralocorticoid/NN)) binding/NN sites/NNS))) (VP was/VBD (VP increased/VBN (NP *-54/-NONE-) (PP in/IN (NP-COOD (NP hypertensives/NNS) vs/CC (NP normotensives/NNS))))) ./.)
(S (NP-SBJ (NP The/DT treatment/NN) (PP with/IN (NP the/DT ACE/NN inhibitor/NN captopril/NN))) (VP led/VBD (PP to/TO (NP (NP activation/NN) (PP of/IN (NP hormone-receptor/NN interactions/NNS))))) ./.)
(S (NP-SBJ There/EX) (VP was/VBD (NP-PRD (NP a/DT (ADJP more/RBR marked/JJ) rise/NN) (PP of/IN (NP (NP the/DT number/NN) (PP of/IN (NP receptors/NNS)))) (PP in/IN (NP-COOD (NP (ADJP (ADJP middle-aged/JJ) (PRN -LRB-/-LRB- (NP (QP 44-55/CD) years/NNS) -RRB-/-RRB-)) hypertensives/NNS) vs/CC (NP (ADJP (ADJP elderly/JJ) (PRN -LRB-/-LRB- (NP (QP 61-80/CD) years/NNS) -RRB-/-RRB-)) subjects/NNS)))) (PP-TMP after/IN (NP captopril/NN treatment/NN))) ./.)
